Form 4: NextCure Executive Kevin G. Shaw Acquires Stock Options

NextCure's Senior Vice President and General Counsel, Kevin G. Shaw, acquired 66,125 stock options on January 31, 2025.

Summary

• Kevin G. Shaw, Senior Vice President and General Counsel at NextCure, Inc., acquired 66,125 employee stock options on January 31, 2025.
• The exercise price of these options is $0.8048 per share.
• One fourth of the options will vest on January 31, 2026, with the remainder vesting in 36 monthly installments starting February 28, 2026.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns executive interests with shareholder value. There is no indication of any negative sentiment.

Positives

• The acquisition of stock options by a key executive like Kevin G. Shaw can be seen as a positive sign of confidence in the company's future.

Future Outlook

This filing reflects the ongoing equity-based compensation practices of the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one fourth after one year and the remainder over 36 months is a typical vesting schedule.
• The exercise price of $0.8048 is likely based on the market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially increase the number of shares outstanding if the options are exercised, which could dilute existing shareholders.

Key Dates

Keywords

stock options, insider trading, executive compensation, NextCure, NXTC, vesting, equity